AstraZeneca signs US$5 billion research deal with China’s CSPC
AstraZeneca has signed a research agreement worth more than US$5 billion with Chinese drugmaker CSPC Pharmaceutical Group, the Anglo-Swedish drugmaker said on Friday.
ADVERTISEMENT
ADVERTISEMENT
AstraZeneca has signed a research agreement worth more than US$5 billion with Chinese drugmaker CSPC Pharmaceutical Group, the Anglo-Swedish drugmaker said on Friday.